Skip to content
Catalyst

(R)-carnitineFinding

(R)-carnitine decreases alanine aminotransferase

lowersVery limited evidenceFindingreplicated ×3

01 · The sentence it was drawn from

“The results demonstrated that carnitine supplementation significantly reduced homeostasis model assessment of insulin resistance (HOMA-IR) (WMD: -0.91; 95 % CI: -1.11, -0.72; p < 0.001, I2 = 0.0 %) and the levels of aspartate aminotransferase (AST) (WMD: -16.62; 95 % CI: -28.11, -5.14; IU/l; p = 0.005, I2 = 93.5 %), alanine aminotransferase (ALT) (WMD: -33.39; 95 % CI: -45.13, -21.66; IU/l; p < 0.001, I2 = 93.4 %), and triglycerides (TG) (WMD: -22.13; 95 % CI: -38.91, -5.34; mg/dl; p = 0.01; I2 = 0.0 %).”
Quoted verbatim from The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
This finding among the 65 findings on its endpoint

(R)-carnitine

Alanine aminotransferase

lowers

Effect as reported

−33.39mean difference

CI −45.13 to −21.66

Who
Patients with non-alcoholic fatty liver disease; meta-analysis of 5 randomized placebo-controlled trials (334 individuals)
Dose studied
not reported

Very limited evidencePMID 31987257 · 2020

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

03 · The paper

Complementary therapies in medicine
What else it reported4 findings · 1 compound · 4 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M701TWX2RC5A6DXRTQN9JGA6